Skip to content

Effects of Adlay Extract Formula on Dysmenorrhea in Women

Effects of Adlay Extract Formula on Dysmenorrhea in Women

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06637553
Acronym
ECCEMPW
Enrollment
77
Registered
2024-10-15
Start date
2017-10-14
Completion date
2018-09-28
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysmucorrhea, Menstrual Pain

Keywords

Dysmenorrhea, Adlay formula

Brief summary

Due to the Westernization of diet in Taiwan, the risk of many chronic diseases has increased. Some diseases and improper treatments are closely related to menstrual pain and functional impairment in women. Women's menstrual pain can affect daily life and work, and many plant-based extracts have been found to have beneficial effects on alleviating menstrual pain. Therefore, the development of functional health food that can improve menstrual pain is of great significance for health promotion and the market. Coix seed has long been understood to have properties beneficial for menstrual health. Scientific research has demonstrated its effectiveness in alleviating menstrual pain. The primary ingredient, coix seed extract, has been extensively studied, and its efficacy has been confirmed through numerous clinical and animal experiments. This study aims to scientifically investigate the effect of coix seed compound extract on menstrual pain in women and to understand its underlying mechanism and potential benefits.

Detailed description

This study investigates the efficacy of coix seed compound extract in alleviating menstrual pain and its potential impact on inflammatory markers. The study will enroll women aged 20-40 with a history of moderate to severe menstrual pain, especially on the first or second day of menstruation. The study includes participants with regular menstrual cycles of 21-35 days. Participants who meet the inclusion criteria will undergo a series of blood tests throughout the study. Blood samples (10cc each) will be collected three times-once before the intervention, and twice during the treatment period-to assess inflammatory markers, including IL-6 and cytokines. The samples will be analyzed for blood biochemical parameters and stored for future evaluations. The intervention involves the daily administration of 20 grams of coix seed compound extract dissolved in 200cc of hot water, starting one day before menstruation and continuing for the duration of each menstrual cycle during the study period. The compound includes a mixture of coix seed extract, grape seed extract, and cranberry extract, which are recognized as safe food ingredients. Potential side effects are expected to be minimal due to the natural composition of the extract. However, participants will be monitored for any adverse reactions. In the event of side effects, participants will be advised to discontinue the extract and consult with the research team.

Interventions

COMBINATION_PRODUCTAdlay formula

The extract will be administered at a dose of 20 grams dissolved in 200cc of hot water once daily

COMBINATION_PRODUCTPlacebo

Same weight as the adlay formula but did not include the active compound

Sponsors

Taipei Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Women aged 20-40 * Women who have experienced menstrual pain in recent years, especially on the first or second day of menstruation * Women whose menstrual pain affects their daily life * Women with a regular menstrual cycle of 21-35 days, with menstruation lasting 3-7 days

Exclusion criteria

* Pregnant or breastfeeding women, or those planning pregnancy or using birth control * Women with severe gynecological diseases * Women who have undergone uterine surgery or recent pelvic surgery * Women with major diseases such as cancer, heart disease, or thyroid disorders * Women who have used pain relief medication for menstrual pain in the past month

Design outcomes

Primary

MeasureTime frameDescription
Pain reliefPain levels will be measured at baseline and after each menstrual cycle during the 3-month intervention periodPain relief will be assessed using the Visual Analog Scale (VAS), which measures pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable). Participants will report their pain levels at specific time points.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026